The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Arcus Biosciences Inc. | COM | 03969F109 | 33,068 | 3,070,423 | SH | OTR | 1,2,3 | 0 | 3,070,423 | 0 | |
| Arcus Biosciences Inc. | COM | 03969F109 | 5,067 | 470,427 | SH | OTR | 3 | 0 | 470,427 | 0 | |
| Constellation Pharmceticls I | COM | 210373106 | 10,245 | 2,554,850 | SH | OTR | 3 | 0 | 2,554,850 | 0 | |
| Constellation Pharmceticls I | COM | 210373106 | 8,514 | 2,123,088 | SH | OTR | 3 | 0 | 2,123,088 | 0 | |
| Gritstone Oncology Inc. | COM | 39868T105 | 47,940 | 3,102,934 | SH | OTR | 1,2,3 | 0 | 3,102,934 | 0 | |
| Immune Design Corp. | COM | 45252L103 | 1,040 | 800,000 | SH | OTR | 1,2,3 | 0 | 800,000 | 0 | |
| Immune Design Corp. | COM | 45252L103 | 4,111 | 3,161,942 | SH | OTR | 3 | 0 | 3,161,942 | 0 | |
| Immune Design Corp. | COM | 45252L103 | 3,485 | 2,681,000 | SH | OTR | 3 | 0 | 2,681,000 | 0 | |